-1753359733653.webp&w=3840&q=75)
2025 NOSCM | HER2 Positive Breast Cancer: Individualizing Treatment to Biology and Response
0% Complete
Course Overview
Dr. Mark Pegram discussed the DESTINY-Breast09 trial, showing superior PFS with tucatinib plus pertuzumab.
Course Content
This material is non-CME, no credits are available, and a certificate will not be provided upon completion.
Course Details
- Duration
- 0.00 hour
- Released
- Jul 25, 2025
- Last Review
- Jul 25, 2025
- Expires
- Jul 25, 2026
Target Audience
Physicians
Nurses
Pharmacists
Physician Associates
Faculty & Disclosure
Faculty
Mark Pegram, MD
Accreditation
NA
Related Courses
2026 NOSCM | We Should Change Treatment Based on Emerging Mutations in Patients with ER+/HER2- Metastatic Breast Cancer (NO)
0.00 Credits
1 Chapter
Breast
Free
2026 NOSCM | We Should Change Treatment Based on Emerging Mutations in Patients with ER+/HER2- Metastatic Breast Cancer (YES)
0.00 Credits
1 Chapter
Breast
Free